Pyoderma gangrenosum
Pyoderma gangrenosum dia aretina hoditra tsy fahita firy, izay mahatonga ny pustules na nodules maharary lasa fery izay mitombo tsikelikely. Pyoderma gangrenosum dia tsy mifindra. Ny fitsaboana dia mety ahitana corticosteroids, cyclosporine, na antibody monoclonal isan-karazany. Na dia mety hisy fiantraikany amin'ny olona amin'ny taona rehetra aza izany, dia misy fiantraikany amin'ny ankamaroan'ny olona eo amin'ny 40 sy 50 taona.
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
tongotr'olona voan'ny colitis.
References
Pyoderma gangrenosum dia aretina hoditra tsy fahita firy izay miteraka fery maharary misy sisiny mena na volomparasy. Izy io dia sokajiana ho aretina mamaivay ary anisan'ny vondrona antsoina hoe dermatoses neutrophilic. Ny anton'ny pyoderma gangrenosum dia sarotra, misy olana amin'ny hery fiarovana voajanahary sy adaptive amin'ny olona izay mora voan'ny fototarazo. Vao haingana, ny mpikaroka dia nifantoka tamin'ny follicule volo ho toerana mety hiaingan'ny aretina.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum dia aretina hoditra tsy fahita firy izay miteraka fery maharary. Na dia tsy takatsika tanteraka aza ny anton'izany, dia fantatsika fa tafiditra ao anatin'izany ny fitomboan'ny asan'ny sela immune sasany. Tsy mbola mora ny fitsaboana ny aretina. Manana fanafody isan-karazany isika izay manafoana ny hery fiarovana na manova ny asany. Ankoatra ireo dia mifantoka amin'ny fitsaboana ny ratra sy ny fitantanana ny fanaintainana koa izahay. Ny corticosteroids sy ny cyclosporine dia matetika no safidy voalohany amin'ny fitsaboana, saingy tato ho ato, nisy fikarohana bebe kokoa momba ny fampiasana fitsaboana biolojika toy ny TNF-α inhibitors. Ireo biolojika ireo dia tiana kokoa, indrindra amin'ny marary manana aretina hafa amin'ny areti-mifindra, ary ampiasaina aloha izy ireo amin'ny fizotran'ny aretina.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
